Celebration of the Signing of the Kingdom’s First Landmark Agreement to Transfer Technology of Oral Cytotoxic Oncology Drugs Technology
IOn the pursuite towards achievingof vision 2030 of the kingdom of Saudi Arabia May , a partnership Joint Venture agreement was signed between Nasaq Al-Injaz Company for Development and Commercial Investment, one of the companies of the renowned Al-Zahran Group, represented by Mr. Badr Ghurmallah Al-Zahrani, Chairman of the Group’s Board of Directors, and Macleods Pharmaceuticals of India, one of top 10 pharma companies in India and its affiliated research center, represented by Mr. Vijay Agarwal, CEO of the company.
This project which was inked on 27th May 2025, marks a major milestone in the production of vital chronic disease medications, specifically oral oncology drugs, which currently have no alternatives generics available in the Kingdom. The foreign party Macleods will transfer the technology for these products, which require specific standards in the design and construction of the manufacturing plant to comply with global pharmaceutical benchmarks.
In addition to oncology drugs, both parties have agreed to establish a separate plant to manufacture the latest medications for other chronic illnesses such as heart disease, diabetes, asthma, psychiatric disorders, and also the newest treatments for acute and chronic migraines.
Production from the project is expected to be available in phases, with the first phase beginning within 18 months of the agreement’s signing.
The ceremony has been be attended by prominent figures from the pharmaceutical industry, led by His Excellency Dr. Abdullah Al-Abdulqader, the founder of the pharmaceutical industry in Saudi Arabia through the pioneering company SPIMACO, as well as a former member of the Shura Council and Vice President of the Anti-Corruption Authority (Nazaha), in addition to senior officials from the Saudi Food and Drug Authority.
